新闻中心

News Center

2017-Foncoo Public Welfare-Caring for the mentally ill

Release Time

2022-06-22 10:24

   In December 2017, the company contacted the Changge Psychiatric Rehabilitation Hospital through the Henan Disabled Persons Welfare Foundation, and provided 8 poor mentally ill patients with a one-year drug treatment fee of 50,000 yuan in the form of donations. The purpose of this public welfare activity is to help mentally ill patients receive timely and effective treatment, and to help the families of poor patients reduce the burden.

Related News

Foncoo Pharmaceutical participated in the 19th National Psychiatry Academic Conference of the Chinese Medical Association

Sponsored by the Chinese Medical Association and the Psychiatry Branch of the Chinese Medical Association, and organized by the Chongqing Medical Association, the Psychiatry Branch of the Chongqing Medical Association, the First Affiliated Hospital of Chongqing Medical University, and the University City Hospital Affiliated to Chongqing Medical University The conference and the Academic Conference on Child and Adolescent Psychiatry were successfully held at Chongqing Yuelai International Conference Center from December 21 to 24, 2021.

2022-05-25

图片名称

2021-Foncoo Public Welfare

On October 15, 2021, Foncoo Pharmaceutical donated 100,000 yuan in cash to the "Gu Xueqiu Pharmacy Education Fund" public welfare student aid project of the Beijing Renren Public Welfare Foundation-Shenyang Pharmaceutical University.

2022-05-25

图片名称

Foncoo Pharmaceutical's corporate culture 5.0 was officially released

Official announcement! Seriously, don't be distracted!

2022-05-25

图片名称

Foncoo Pharmaceutical participated in the 16th National Academic Conference on Psychiatric Hospital Management

On October 29-31, 2021, the 16th National Academic Conference on Psychiatric Hospital Management, hosted by the Chinese Hospital Association and the Chinese Hospital Association Psychiatric Hospital Branch, was held in Chongqing.

2022-05-25

图片名称

"Bupropion Hydrochloride Sustained-Release Tablets (II)" exclusively sold by Foncoo Pharmaceuticals was approved in China

Recently, "Bupropion Hydrochloride Sustained-Release Tablets (II) (150mg, 300mg)", exclusively sold by Pangu Pharmaceuticals (Mainland China), was approved by the State Drug Administration and deemed to have passed the consistency evaluation. The product, developed by Shanghai Xuantai Pharmaceuticals, was previously approved by the FDA in August 2017 and was marketed in the United States.

2022-05-25

图片名称

Foncoo Pharmaceutical participated in the 9th China Schizophrenia Forum

From October 22 to 24, 2021, the "Ninth China Schizophrenia Forum" was grandly held in Wuhan. The theme of this forum is "Infection, Inflammation and Schizophrenia".

2022-05-25

图片名称